

Computational challenges in genome wide association studies: data processing, variant annotation and epistasis

Pablo Cingolani

PhD.

School of Computer Science

McGill University

Montreal, Quebec

March 2015

A thesis submitted to McGill University in partial fulfillment of the requirements of
the degree of Doctor of Philosophy

Pablo Cingolani 2015

CHAPTER 1

Epistatic GWAS analysis

1.1 Preface

In recent years, over 80 genetic loci related to T2D have been identified [44, 10]. Nevertheless, the overall effect sizes of these loci account for less than 10% of the overall disease predisposition [39]. This poses the question of why, given that so much efforts has been directed at finding the genetic components of this disease, the loci found so far have such modest effects. This lack of large genetic effects, known as the “missing heritability” problem, does not only arise in T2D but also in almost all complex traits. In recent studies about missing heritability [67, 68] it was proposed that this effect might be partly explained by taking into account epistasis (i.e. gene interactions).

In this chapter, we propose a novel framework that takes into account putative epistatic interactions into genome wide association studies (GWAS).

Although this thesis focusses on the development of computational approaches that could be applied to the study of a number of complex diseases, our focus has been on type II diabetes mellitus (T2D), a complex disease first described by the Egyptians in 1500 BCE. Later the Greeks in 230 BCE used the term “diabetes” meaning “pass through” (or “siphon”) denoting the constant thirst and frequent urination of the patients. In the 1700s the term “mellitus” (from honey) was added to denote that the urine was sweet and would “attracts ants”.

Diabetes symptoms include frequent urination, thirst, and constant hunger, high blood sugar (hyperglycemia) and insulin resistance. Long term complication from T2D may include eyesight problems, heart disease, strokes and kidney failure. Type II diabetes, is highly correlated with obesity and disease rate has increased dramatically during the last 50 years. According to the World Health Organisation the prevalence of diabetes is 9% in adults and an estimated 1.5 millions deaths were caused by diabetes in 2012 [24], which is predicted to be the 7th leading cause of death by 2030. The costs associated to treating diabetes patients only in the U.S. are estimated around \$245 billion dollars.

The rest of the chapter is published in: **P. Cingolani**, R. Sladek, M. Blanchette, “A co-evolutionary approach for detecting epistatic interactions in genome-wide association studies”

1.2 Abstract

Motivation. Epistasis, broadly defined as genetic interactions, is one of the likely causes why genome-wide association studies (GWAS) account for a small portion of heritable disease risk. Due to their high complexity, reduced statistical power and sometimes prohibitive computational requirements, epistatic GWAS have rarely been performed.

Methods. In this paper, we propose a novel methodology for analysing putative epistatic interactions by combining multiple genome alignments and sequencing information. Using protein structures for individual and co-crystallized complexes information and genome wide multiple species alignment we create a co-evolutionary model that allows the calculation of the posterior probability of physical interaction

between residues given evolutionary data. These probabilities are then used as the interaction priors for an epistatic GWAS analysis as basis for genome wide Bayesian framework.

Results. Our optimized algorithms can be applied to genome wide scale sequencing studies for tens of thousands of samples, that typically yield millions of variants. We applied our approach to a large type II diabetes (T2D) case-control cohort and inferred a number of putative interactions associated with increased risk of developing T2D.

Availability. Our code is publicly available at github.com/pcingola/Epistasis

1.3 Introduction

Genetic studies aim to discover how a phenotype of interest, such as disease risk or height, is affected by an individual’s genetic background. Genome wide association studies (GWAS) are powerful techniques aimed at finding statistical associations between a phenotype and genetic variants [8]. Although several genetic variants related to different phenotypes have been found, variants discovered in GWAS so far can only explain a small part for the phenotypic heritability. For instance, all genetic variants associated to height collectively account for few centimetres in the offspring’s height [61]. Similarly the known variants related to type 2 diabetes risk collectively explain only 5% to 10% of the overall variance in disease predisposition [44, 10]. This problem is known as “missing heritability” [39] and recent theories suggest that genetic interactions (epistasis) might play an important role in it [67, 68].

The foundations for epistasis [20], have been proposed almost a hundred years ago by Bateson (1909) and Fisher (1918). It was the latter who coined the term to

denote a “statistical deviation of multi-locus genotype values from an additive linear model for the value of a phenotype” [20]. There is evidence of such interactions being involved in complex diseases. For instance an interaction between BACE1 and APOE4 having a significant association with Alzheimer’s disease has consistently been replicated in different studies [9]. Many types of situations can lead to epistatic interactions. Among them, perhaps the most common involved pairs of variants that encode amino acids whose physical interactions is regulated for their function.

One of the main problems in finding association between interactions and disease is that out of the whole set of molecular interactions (the interactome) only a small part of it has been characterized [56]. Interacting proteins can be identified experimentally through several types of approaches (yeast two hybrid, protein fragment complementation assay, glutathione-s-transferase, affinity purification coupled to mass spectrometry, tandem affinity purification, etc. [52]) and large databases of protein-protein interactions are now available for human [54, 52]. In almost all cases, these methods identify the presence of an interaction between proteins but do not discern the exact residues mediating such interactions. Furthermore, it is estimated that up to 80% of the human protein-protein interactions remains unknown [56].

These issues can be partially addressed using computational predictions of either pairs of interacting proteins or interacting residues [53]. A type of approaches that has been gaining popularity recently is one that makes use of the plethora of genomic sequences available for species other than human in order to discover evolutionary evidence of selective pressure on pairs of residues to identify interacting sites and interfaces [40]. Interacting residues and their neighbours may then be subject to

compensating epistasis, where a mutation at a residue in one protein may be compensated by another mutation at a residue in the second protein [45]. For example assuming that evolutionary pressure acts on both interaction sites simultaneously, co-occurring compensatory mutations can become fixed in the population with higher probability than non-compensatory ones. In light of this hypothesis, one can use statistical methods on multiple sequence alignments of proteins from different organisms to find coevolving sites. This types of approaches has been used to identify coevolving sites both within a protein (e.g. N-terminal and C-terminal domains in PKG protein [22], GroES-L chaperoning system [50], α and β haemoglobin subunits [45]), and between interacting proteins (e.g. G-protein coupled receptors and protein ligands [22]).

Many methods exist to find putative interaction loci, both within and across proteins, based on evolutionary evidence (see [16] for a review). One of the simplest methods for inferring co-evolution uses mutual information between two loci [40] in a multiple sequence alignment. However, methods based on correlation or mutual information are known to have systematic biases due to the fact that they ignore phylogenetic relationships [16], or sequence heterogeneity problems [59]. More sophisticated methods, such as DCA [43], PSICOV [28] or mdMI [7] try to overcome these biases, however they are usually not suitable for GWAS-scale analysis for two main reasons. First, they require multiple alignments of a very large number of sequences (ranging from 400 to $25L$, where L is the length of the protein [7]), and such depth is not usually available at whole genome scale. Second, they are computationally demanding (e.g. running for minutes or even days for each interacting pair of

proteins being considered), making them unsuitable for analyses involving millions of variants spanning over thousands of proteins. Furthermore, a recent study shows that overall agreement between methods is not high (65% or less) and predictive power is quite low (only 6% of the “top scoring pairs” are real interactions) [7].

Applying epistatic interaction models to GWAS studies is a challenging problem for several reasons: i) interaction models are by definition non-linear [20]; ii) analyzing all order N variant combinations requires great computational power and efficient algorithms because the number tests grows exponentially with N [47]; iii) multiple hypothesis testing correction can render association tests underpowered for all but very large cohorts [20, 47]; and iv) there is no consensus of what genetic interaction means, which is reflected in the difficulty to find a unified model [47, 38]. For all these reasons and due to the lack of sequencing cohorts large enough to detect these interactions, the application of epistatic models to sequencing studies has not been widespread. Furthermore, there is no clear consensus on the required sample size to detect epistatic interactions. Depending on phenotypic effect size and variant’s allele frequency some estimates assume in the order of 10,000 to 500,000 cases [29] to be required. Such cohorts are now becoming feasible due to improvements and cost reductions in sequencing technology.

Approaches for epistatic GWAS do exist and they apply a wide array of methodologies. In [66], the authors infer epistatic probabilities by noting that interactions create linkage disequilibrium patterns in the disease population. A Bayesian framework is applied in [65] taking into account several risk models, using Dirichlet priors the distribution for each model can be solved analytically, then the combined model’s

posterior distribution is calculated using an MCMC sampling technique. In [1], the authors look for over / under-represented allele pairs in a given population by performing an analysis of imbalanced allele pair frequencies. Finally, finding interacting variants can be viewed as an attribute selection problem, thus many machine learning methodologies have been proposed [42]. While all algorithms have relative advantages, there is no standard in epistatic analysis, we believe that we can create better methods by combining other sources of biological information, such as evolutionary evidence.

In this work we propose an approach to prioritize pairs of variants identified in case/control cohorts by combining genome wide association with epistatic interaction models. In a nutshell, our method uses recently computed 100-way vertebrate genome alignments [4] to calculate interaction posterior probabilities for any given pair of residues in human proteins. This is achieved by contrasting the likelihood of the observed pair of alignment columns under a joint substitution model that factors in dependencies between interacting sites, and a null model of independent evolution. These posterior probabilities are then used as priors to modulate the evidence of epistatic interaction derived from GWAS data. Our implementation is sufficiently efficient to be applied to GWAS-scale datasets of tens of thousands of samples. Finally we apply this methods to a cohort of $\sim 13,000$ individuals in a case-control study of type II diabetes (for study details, see [41]) and identify suggestive associations of putatively epistatic interactions.

1.4 Methods

Our epistatic GWAS analysis pipeline involves three key steps, as shown in Figure 1–1. First, we learn a co-evolutionary substitution rate matrix for pairs of amino acids that are in contact in proteins. Second, we analyze a GWAS data set to identify pairs of non-synonymous SNPs that show (possibly weak) evidence of epistasis. Third, for each pair of SNP identified in step 2, we measure the evidence of co-evolution of the pair of encoded amino acids, and combine it with the GWAS evidence by calculating the Bayes factor.

1.4.1 Substitution model for pairs of interacting amino acids

In this section, we describe how we estimate two substitution rate matrices. The first is the usual 20×20 substitution rate matrix Q describing the evolution of individual amino acids. The second, Q_2 , is a 400×400 substitution rate matrix for pairs of interacting residues.

We used the 100-way vertebrate multiple sequence alignment and accompanying phylogenetic tree T available from the UCSC Genome Browser [30]. This alignment includes the DNA sequences of 100 species whose genome is completely or nearly completely sequenced, with 12 primates, 44 non-primates eutherians, 5 marsupials, 14 birds, 6 reptiles, 16 ray-finned fish and 8 lobe-finned fish. The multiple alignment is performed using “multiz” algorithm [4, 32].

From the $\sim 21,000$ human protein structures (resolution less than 3 \AA) available in Protein Data Bank, we extracted a set of $\sim 770,000$ pairs of “within protein interactions” residues, defined as pairs of residues from the same protein where at least one pair of atoms is within 3 \AA or less. Similarly, from the set of $\sim 5,700$




Figure 1–1: Complete pipeline example

models of co-crystallized complexes in PDB, we extracted a set of $\sim 12,000$ pairs of “protein-protein interacting” residues, defined as amino acids from different proteins that satisfy the same distance criterion.

To derive rate matrix Q , we consider the complete set of $n \sim 22 \times 10^6$ protein coding sites present in the alignment, irrespective of the presence or absence of contacts. Q is obtained following classical sequence evolution theory ([63, 19]). First, for each pair of species s_i and s_j , we obtain $c_i(a)$ defined as the count of amino acid a in species s_i , and $c_{i,j}(a, b)$ defined as the number of sites that have had a transition from amino acid a in s_i to b in s_j . Stationary probability of amino acid a in genome s_i is then defined as $\pi_i = c_i(a)/n$. Assuming a time reversible model, we get the frequency of change from a to b : $f_{i,j}(a, b) = f_{j,i}(a, b) = (c_{i,j}(a, b) + c_{j,i}(a, b))/(2n)$. Let $P_{i,j}$ be the amino acid transition probability matrix from s_i to s_j , i.e. $P_{i,j}(a, b)$ is the probability that species s_j has amino acid b given that species s_i has amino acid a . Then $P_{i,j}$ is obtained through the relation $f_{i,j}(a, b) = \pi_i(a) \cdot P_{i,j}(a, b)$, or $P_{i,j}(a, b) = f_{i,j}(a, b)/\pi_i(a)$. Let $t_{i,j}$ be the total branch length between s_i and s_j (obtained from the phylogenetic tree). Assuming time reversibility, we have $P_{i,j} = e^{Q \cdot t_{i,j}}$, and thus $Q = \log[P_{i,j}/t_{i,j}]$ [63]. Taking into account the estimation error, the equation becomes $\hat{Q}(t_i + t_j) = Q = \log[P_{i,j}/t_{i,j}] + \epsilon_{i,j}$, where $\epsilon_{i,j}$ is an error matrix. Under the assumption that the mean error is zero, we can approximate the rate matrix by the calculating an average of all estimates:

$$\begin{aligned}
\hat{Q} &= \frac{1}{N(N-1)/2} \sum_{i < j} \hat{Q}(t_i + t_j) \\
&= \frac{2}{N(N-1)} \sum_{i < j} \frac{1}{t_i + t_j} \log[\hat{P}(t_i + t_j)]
\end{aligned}$$

The much larger substitution matrix Q_2 describes the substitution rate from any pair of amino acids (a, b) to any other pair (c, d) . It is derived similarly to Q , but considering only pairs of amino acids from the set of within protein interacting pairs of amino acids. We only take into account amino acids pairs within the same chain, that are separated by 20 amino acids or more.

1.4.2 Calculating likelihood of individual and pairs of alignment columns

Given a substitution rate matrix Q , the likelihood $L_1[MSA(i)]$ of an alignment column $MSA(i)$ assigning an amino acid to each leaf in the tree T is calculated using the well known Felsenstein algorithm [19]. This is achieved in time $O(N \cdot |\Sigma|^2)$, where $|\Sigma| = 20$ and N is the number of sequences in the alignment. Given matrix Q_2 , the same algorithm can be used to compute the likelihood $L_2[MSA(i), MSA(j)]$ of a pair of alignment columns $(MSA(i), MSA(j))$, but now in time $O(N \cdot |\Sigma|^4)$.

A test for co-evolution of two positions i, j of the same or different proteins is obtained using the likelihood ratio under the two models:

$$L_C[MSA(i), MSA(j)] = \frac{L_2[MSA(i), MSA(j)]}{L_1[MSA(i)] \cdot L_1[MSA(j)]}$$

where the denominator assumes that the amino acids i and j evolve independently. Similarly, the log-likelihood is defined as

$$\ell_C[MSA(i), MSA(j)] = \log \left[\frac{L_2[MSA(i), MSA(j)]}{L_1[MSA(i)] \cdot L_1[MSA(j)]} \right] \quad (1.1)$$

Because the calculations described in this section will need to be performed on a very large number of pairs of sites, optimizations we are required to ensure manageable running time. First, pre-calculation of matrix exponentials $P(t) = e^{Qt}$ is necessary for all values of t corresponding to individual branch lengths. Another optimization (“constant-tree caching”) is used to cache likelihood values for subtrees of the phylogenetic tree where all nodes have the same amino acid values. This optimization results in speed-up only if the phylogenetic tree remains constant throughout the genome, which is the case in our model.

1.4.3 GWAS model

Consider a GWAS with N_S samples (individuals) and N_V variants, we use the standard notation for phenotypes and code them as $d_s = 1$ when individual s is affected by disease and $d_s = 0$ if it is “healthy”. Let $\bar{d} = [d_1, \dots, d_{N_S}]$ be a phenotype vector and $g_{s,i} \in \{0, 1, 2\}$ a genomic variant for sample s at locus i . A logistic model of disease risk [3] is

$$\begin{aligned} p_{s,i} &= P(d_s = 1 | g_{s,i}, \bar{\theta}) \\ &= \phi(\theta_0 + \theta_1 g_{s,i} + \theta_2 c_{s,1} + \theta_4 c_{s,2} + \dots) \\ &= \frac{1}{1 + e^{\theta_0 + \theta_1 g_{s,i} + \theta_2 c_{s,1} + \theta_4 c_{s,2} + \dots}} \\ &= \phi(\bar{\theta}^T \bar{g}_{s,i}) \end{aligned}$$

where $\phi(\cdot)$ is the sigmoid function, $c_{s,1}, c_{s,2}, \dots$ are covariates for each individual s (these covariates usually include sex, age and eigenvalues from population structure analysis [48]), $\bar{g}_{s,i} = [1, g_{s,i}, c_{s,1}, c_{s,2}, \dots, c_{s,N_C}]$, and $\bar{\theta} = [\theta_1, \theta_2, \dots, \theta_m]$. The parameter estimates $\bar{\theta}$ are obtained by solving the maximum likelihood equation

$$\begin{aligned} L(\bar{\theta}) &= \prod_{s=1}^{N_S} P(d_s | \bar{\theta}, g_{s,i}) \\ &= \prod_{s=1}^{N_S} p_{s,i}^{d_s} (1 - p_{s,i})^{1-d_s} \\ &= \prod_{s=1}^{N_S} \phi(\bar{\theta}^T \bar{g}_{s,i})^{d_s} (1 - \phi(\bar{\theta}^T \bar{g}_{s,i}))^{1-d_s} \end{aligned}$$

Using this model, we have two hypotheses: i) the null hypothesis, H_0 , assumes that genotype does not influence disease probability (i.e. $\theta_1 = 0$). ii) the alternate hypothesis, H_1 , assumes that the genotype does influence disease probability (i.e. $\theta_1 \neq 0$). We can compare these two hypotheses using a likelihood ratio test. We define

$$L_G = \frac{L(\bar{\theta} | H_1)}{L(\bar{\theta}' | H_0)} \quad (1.2)$$

$$\ell_G = \log [L_G] = \log \left[\frac{L(\bar{\theta} | H_1)}{L(\bar{\theta}' | H_0)} \right] \quad (1.3)$$

where $\bar{\theta}'$ and $\bar{\theta}$ are the maximum likelihood estimates for null and alternate model respectively. According to Wilk's theorem [60], the log likelihood ratio has a χ_1^2 distribution under the null hypothesis, so we can easily calculate a p-value.

Next, we extend the logistic model to accommodate interacting loci. For an individual (sample s), we model interactions between two genetic loci i and j , having genotypes $g_{s,i}$ and $g_{s,j}$, by extending the logistic model

$$P(d_s|g_{s,i}, g_{s,j}, H_1) = \phi[\theta_0 + \theta_1 g_{s,i} + \theta_2 g_{s,j} + \theta_3 (g_{s,i} g_{s,j})] \quad (1.4)$$

$$\dots + \theta_4 c_{s,1} + \dots + \theta_m c_{s,N_{cov}}] \quad (1.5)$$

$$= \phi(\bar{\theta}^T \bar{g}_{s,i,j}) \quad (1.6)$$

where $\bar{g}_{s,i,j} = [1, g_{s,i}, g_{s,j}, (g_{s,i} g_{s,j}), c_{s,1}, c_{s,2}, \dots, c_{s,N_{cov}}]^T$. An implicit assumption in this equation is that $g_{s,i}$ and $g_{s,j}$ are not correlated (e.g. they are not located in the same LD-Block). This can be enforced either by using haplotype structure information (e.g. from HapMap) or by limiting the application of the model to variants either in different chromosomes or sufficiently distant (say $> 1Mb$). The null hypothesis H_0 assumes that variants act independently

$$P(d_s|g_{s,i}, g_{s,j}, H_0) = \phi[\theta'_0 + \theta'_1 g_{s,i} + \theta'_2 g_{s,j} + \theta'_3 c_{s,1} + \dots] \quad (1.7)$$

$$= \phi(\bar{\theta}'^T \bar{g}'_{s,i,j}) \quad (1.8)$$

where $\bar{g}'_{s,i,j} = [1, g_{s,i}, g_{s,j}, c_{s,1}, c_{s,2}, \dots, c_{s,N_{cov}}]^T$.

We investigated several algorithms for logistic regression parameter fitting. The fastest convergence is obtained using Iterative Reweighted Least Squares (IRWLS [14]) and Broyden-Fletcher-Goldfarb-Shanno algorithm (BFGS [5]) with some code

optimizations. In most cases, IRWLS converges faster, so it was selected as the default implementation in our analysis.

Another way to compare the null hypothesis to the alternative hypothesis, is using a Bayesian formulation [31, 58]

$$\begin{aligned} P(H_1|\mathcal{D}) &= \frac{P(\mathcal{D}|H_1)P(H_1)}{P(\mathcal{D})} = \frac{\int P(\mathcal{D}|\bar{\theta}, H_1)P(\bar{\theta}|H_1)P(H_1)d\bar{\theta}}{P(\mathcal{D})} \\ \Rightarrow \frac{P(H_1|D)}{P(H_0|D)} &= \frac{\int P(\mathcal{D}|\bar{\theta}, H_1)P(\bar{\theta}|H_1)d\bar{\theta}}{\int P(\mathcal{D}|\bar{\theta}', H_0)P(\bar{\theta}'|H_0)d\bar{\theta}'} \frac{P(H_1)}{P(H_0)} = BF \frac{P(H_1)}{P(H_0)} \end{aligned}$$

where BF , the ratio of the two integrals, is the Bayes factor. Using a Bayesian formulation has two main advantages: i) the hypothesis are automatically corrected for model complexity since Bayes factor asymptotically converge to Bayesian Information Criteria (BIC) [31], and ii) we can compare non-nested models. The Bayes factor for the epistatic model becomes:

$$BF_G = \frac{\int \prod_{s=1}^{N_S} \phi(\bar{\theta}^T \bar{g}_{s,i,j})^{d_s} [1 - \phi(\bar{\theta}^T \bar{g}_{s,i,j})]^{1-d_s} P(\bar{\theta}|H_1) d\bar{\theta}}{\int \prod_{s=1}^{N_S} \phi(\bar{\theta}'^T \bar{g}'_{s,i,j})^{d_s} [1 - \phi(\bar{\theta}'^T \bar{g}'_{s,i,j})]^{1-d_s} P(\bar{\theta}'|H_0) d\bar{\theta}'} \quad (1.9)$$

Calculating Bayes factors is challenging and most of the times there are no closed form equations. Calculating the integrals using numerical algorithms is possible, but imposes a significant computational burden thus making it impractical for large datasets, such as GWAS data, even using large computing clusters. We can approximate the integrals using Laplace's method [31]. If $g(x)$ has a maximum at x_0 , it can be shown that

$$\int e^{-\lambda g(x)} h(x) dx \simeq h(x_0) e^{\lambda g(x_0)} \sqrt{\frac{2\pi}{\lambda g''(x_0)}}$$

The multivariate case, for $\bar{x} \in \Re^d$, is analogous: we just need a Hessian matrix instead of a second derivate of $g(\cdot)$

$$\int e^{\lambda g(\bar{x})} h(\bar{x}) d\bar{x} \simeq h(\bar{x}_0) e^{\lambda g(\bar{x}_0)} \left(\frac{2\pi}{\lambda} \right)^{d/2} \left[\frac{\partial^2 g(\bar{x})}{\partial \bar{x} \partial \bar{x}^T} \right]^{-1/2} \quad (1.10)$$

Using equation 1.10 we can try to approximate the complex integrals in equation 1.9 by the transformation $L(\bar{\theta}) = e^{\ell(\bar{\theta})}$, where $\ell(\cdot)$ is the log-likelihood of the data. So, we can use Laplace approximation by using Eq.1.10, at the point of the maximum likelihood. In order to do so, we need to calculate the Hessian matrix in Eq.1.10. Fortunately, for logistic models, we can make a few simplifications. Considering that $L(\bar{\theta}) = \prod_{s=1}^{N_s} \phi(\bar{\theta}^T \bar{g}_s)^{d_s} [1 - \phi(\bar{\theta}^T \bar{g}_s)]^{1-d_i}$, it can be shown that for genotype terms

$$\frac{\partial^2 \ell(\bar{\theta})}{\partial \theta_i \partial \theta_j} = \sum_s g_{s,i} g_{s,j} p_s (1 - p_s)$$

Using analogous derivation for the covariates, we can find an analytic form of the Hessian, which completes the Laplace approximation formula.

Calculating Bayes factors involves using prior parameter distributions. In order to estimate these distributions, we run the logistic regression fitting analysis and plot the parameter distributions for different levels of significance. As expected most

parameters have uni-modal distribution, except for θ_3 , which has a multi-modal distribution. For all parameters, except θ_3 , we use a normal distribution centred at the mean and variance set to one ($\sigma = 1$) even though most times the variance is much smaller. This is done to avoid penalizing outliers too heavily and to have smooth derivatives near the maximum likelihood estimates. For θ_3 , which has a multi-modal distribution, we fit a mixture model parameters using an EM algorithm.

Computational and statistical issues. It is easy to see that the computational burden for the detection of pairs of interacting genetic loci affecting disease risk is significantly larger than in a standard (single variant) GWAS study. A priori all pairs of variants should be analyzed, thus significantly increasing the number of statistical tests. This also reduces the statistical power since the required p-value significance level would be orders of magnitude smaller. A naive approach would estimate that if a typical genetic sequencing study has 10^6 variants, a GWAS on epistatic variants would square that number of statistical tests, thus p-values required for significance would be in the order of $0.05/(10^6)^2 = 5 \cdot 10^{-14}$.

Fortunately these numbers can be reduced significantly. First, in this study, we only concentrate on non-synonymous coding variants. Second, as required by our co-evolutionary model, only variants overlapping a multiple sequence alignment are taken into account (when several multiple sequence alignments overlapped a region, the alignment with the longest number of proteins was selected). Third, if two variants g_i and g_j are such that the interaction term $(g_{s,i}g_{s,j})$ is zero in all samples, which usually happens for pairs of rare variants, then $BF_G = 1$. Fourth, if the variants and the epistatic term $[g_{s,i}, g_{s,j}, g_{s,i}g_{s,j}]$ are linearly dependent, the logistic regression

result will be meaningless, so we can safely skip such variant pairs. Fourth, if one of the variants has high allele frequency respect to the other, all non-zero epistatic terms may lie in the same positions as non-zero genotypes from the low frequency variant, causing logistic regression estimates to artificially inflate the coefficients of the low frequency variant and the epistatic term thus creating an artificially high association (low p-value). So we filter out these variant pairs as well. Finally, we filter out all variants having Hardy-Weinberg p-value of less than 10^{-6} , since these variants also artificially inflate the logistic regression coefficients. Once the results are obtained, we can focus on interactions by further filtering results and keeping variant pairs whose alternative logistic model (see equation 1.4) has small absolute values for θ_1 and θ_2 while having large absolute values for θ_3 , specifically we keep results if $|\theta_3| > K(|\theta_1| + |\theta_2|)$ (based on empirical data, we set $K = 3$).

1.4.4 Putting it all together

In summary, we first calculate the transitions matrices for the Markov models (Q and Q_2) based on observations from protein structures (PDB) and multiple sequence alignments (UCSC’s 100-way). We analyze variants from genome sequencing data first by filtering only for non-synonymous variants, then analyzing all possible pairs of variants and filtering out those that are unsuitable for further analysis (e.g. in linear dependence, deviation from Hardy-Weinberg equilibrium having p-value less than 10^{-6} , etc.). From the pairs of variants that pass filtering, we fit two logistic regression models (null and alternative hypothesis), then calculate a p-value using the log-likelihood ratio, and keeping pairs of variants having p-values below a predefined threshold (10^{-6}). These pairs of variants are then analyzed under our co-evolutionary

model, we find the corresponding columns in the multiple sequence alignment and calculate the likelihoods for the null and alternative models by means of Felsenstein's algorithm (using matrices Q and Q_2 in respectively). Finally, likelihoods from co-evolutionary and logistic regression models are used to calculate the Bayes Factor by means of Laplace's approximation, we extract the co-evolutionary likelihoods from the integrals by assuming independence from genotypes and noting that the probabilities do not depend on θ :

$$\begin{aligned}
BF_T &= \frac{\int \prod_{s=1}^{N_S} \phi(\bar{\theta}^T \bar{g}_{s,i,j})^{d_s} [1 - \phi(\bar{\theta}^T \bar{g}_{s,i,j})]^{1-d_s} P(\bar{\theta}|H_1) d\bar{\theta}}{\int \prod_{s=1}^{N_S} \phi(\bar{\theta}'^T \bar{g}'_{s,i,j})^{d_s} [1 - \phi(\bar{\theta}'^T \bar{g}'_{s,i,j})]^{1-d_s} P(\bar{\theta}'|H_0) d\bar{\theta}'} \\
&\quad \times \frac{L_2[MSA(i), MSA(j)]}{L_1[MSA(i)] \cdot L_1[MSA(j)]} \\
BF_T &= BF_G \times L_C
\end{aligned}$$

1.5 Results

Our approach, which is summarized in Figure ??, involves three main components. First we estimate evolutionary substitution rates for individual amino acids in a protein as well as for pairs of amino acids (either from the same protein or not) that are physically interacting. Given a set of multiple sequence alignment of protein sequences, these evolutionary models can be used to calculate the likelihood of interaction between any two given amino acids, without the need for any structural information. Second, a statistical test for epistasis is developed to identify pairs of non-synonymous SNPs that show (often weak) evidence of interaction in the way

they associate to a given trait. Finally, information from the co-evolution component is combined with that from the epistasis component to give more power to the epistasis test.

1.5.1 Co-evolutionary substitution models

The approach described in Methods was used to obtain substitution rate matrix Q for individual amino acids and Q_2 for pairs of physically interacting residues within the same protein. Unsurprisingly, Q (or more precisely a transition matrix $P(t)$ obtained from Q) is very similar to well known transitions matrices such as PAM [15] (Supplementary Figure 1–7).

The structure of Q_2 , which describes substitution rates between one pair of interacting amino acids to another, is richer (Supplementary Figure 1–8). Of particular interest are the pairs of pairs of amino acids for which the ratio $R(ab, cd) = Q_2(ab, cd)/(Q(a, c) \cdot Q(b, d))$ is large. Those substitution pairs are the ones that are most strongly indicative of an interaction. For example, the case with the highest rate ratio is V.I \rightarrow W.W (i.e. amino acid V switched to W in the one sequence, and amino acid I changed to W in the other). In fact, the top 10 pairs are all transitions to W.W amino acid pairs. This makes sense considering that (i) individual amino acid substitution rates to tryptophan are generally very low, but that (ii) tryptophan pairs are well known β -hairpin stabilizers and are considered as a paradigm for designing stable β -hairpins [51].

Another type of pair transitions with large ratio is the double transitions to a pair of phenylalanine amino acids from a pairs of hydrophobic amino acids (Lysine,

Asparagine, Glutamine, Arginine, Aspartic acid and Glutamic acid). Phenylalanine-Phenylalanine interaction pairs are assumed to conform $\pi - \pi$ interactions which are predicted and experimentally observed to be energetically favourable [27].

1.5.2 Co-evolutionary model validation

We first assessed the ability of our co-evolutionary model to detect interacting sites located within the same protein by computing the likelihood ratio of the evolutionary history of a candidate pair of sites under an co-evolutionary model (Q_2) versus under independence (Q). Although such pairs of sites are unlikely to exhibit evidence of epistasis in GWAS studies (due to linkage), accurate prediction of interacting sites in a given protein are useful for many other purposes, such as protein structure prediction and prediction of the impact of individual mutations. Figure 1–2 shows that interacting sites tend to have higher likelihood ratio scores than non-interacting ones (Mann-Whitney p -value $< 2.2 \times 10^{-16}$). Although the likelihood ratio score it itself cannot perfectly discriminate between the two classes, only 25.9% of non-interacting pairs have a likelihood ratio above the median likelihood ratio of interacting pairs.

To confirm that an evolutionary model estimated based on pairs of interacting sites from the same protein is useful at predicting pairs of interacting sites between proteins, we repeated the same type of analysis on $\sim 3,000$ pairs of interacting (< 3 Å) and $\sim 3,000$ pairs of non-interacting (> 30 Å) residues from distinct proteins, obtained from co-crystal structures in PDB (see Methods). As seen on Figure 1–3, the two classes of sites have substantially different likelihood ratio distributions (Mann-Whitney one sided test: p -value $< 2.2 \times 10^{-16}$), although slightly less so than




Figure 1-2: Histogram of log-likelihood values of pairs of amino acids in contact (red) and not in contact (blue) for amino acids within the protein (PDB). Log-odds of contacting vs non-contacting pairs (black) and smoothed log-odds (dotted grey).

for sites from the same protein. Only 29% of non-interacting sites have a likelihood ratio larger than the median for interacting sites. These empirical distributions, allow us to approximate of the log odds of the “interacting” vs “non-interacting” amino acids distributions as

$$\begin{aligned}
Odds(x) &= \frac{P[L_2(MSA(i), MSA(j)) \geq x]}{P[L_1(MSA(i) \times L_1(MSA(j)) \geq x]} \\
\ell_{odds}(x) &= \log \left[\frac{P[L_2(MSA(i), MSA(j)) \geq x]}{P[L_1(MSA(i) \times L_1(MSA(j)) \geq x]} \right] \\
&\simeq e^{\alpha x} - \beta
\end{aligned}$$

where $\alpha = 0.195$ and $\beta = 1.018$ (in order to avoid bias, the log odds value is capped to 4.0).

Figure 1–4 shows the example of a predicted contact $\ell_C = 7.7$ between *Senp1* and *Sumo1* proteins detected by our method. The co-crystallized structure from PDB highlights the interacting amino acids (less than 3 Å apart) and the corresponding multiple alignment columns.

Although our approach aims at identifying contacting residues from different proteins, it can also be used to predict the presence or absence of interactions between proteins as a whole. We extracted from BioGrid [54] a set of $\sim 3,000$ pairs of human proteins with evidence of interaction, and further required that both proteins belong to the same pathway (MsigDb, C2 groups [55]), and their corresponding genes are expressed in the same tissue (GTex [37], expression of 1 FPKM or more, tissues \in




Figure 1–3: Histogram of log-likelihood values of pairs of amino acids in contact (red) and not in contact (blue) for amino acids in different proteins (co-crystallized entries from PDB). Log-odds of contacting vs non-contacting pairs (black) and smoothed log-odds (dotted grey).

{skeletal muscle, adipose tissue, pancreatic Islets}). We randomly selected as “non-interacting” pairs the same number of pairs amongst those that do not fulfil any of the three conditions.

Let the two proteins considered have amino acid sequences $A = a_1 \dots a_m$ and $B = b_1 \dots b_n$. To obtain the prediction score for this pair of proteins, we identify the pair of length- k substrings $a_i, a_{i+1}, \dots, a_{i+k-1}$ and $b_j, b_{j+1}, \dots, b_{j+k-1}$ that exhibit the strongest support for parallel or anti-parallel interactions

$$\ell_C(k) = \max \left[\sum_{l=0}^{k-1} \ell_C[MSA(a_{i+l}), MSA(b_{j+l})], \sum_{l=0}^{k-1} \ell_C[MSA(a_{i+l}), MSA(b_{j+k-1-l})] \right]$$

where $k = 3$ was determined empirically to provide the best predictive power. As shown in Figure 1–9), prediction accuracy is quite good (p-value $< 2 \cdot 10^{-42}$), taking into account the modest amount of information considered by the model.

1.5.3 Epistatic GWAS analysis

We applied our methods to a cohort of $\sim 13,000$ individuals in a case-control study of type II diabetes [41]. This multi-ethnic study covers exons of unrelated individuals from five major ancestral groups (European descent, South Asian, East Asian, Hispanic and African American descent) using an average sequencing coverage over $80\times$, yielding 1.7 million coding variants. The filters described in Methods section resulted in a number of variant pairs being analyzed less than 50 million. By means of the z-score relationship between Bayes Factor and p-values shown in [23], we can set the GWAS significance threshold for 50 million pairs at $\log_{10}[BF_T] = 8.0$.




Figure 1–4: Example of interaction between amino acid #441 of *Senp1* and #60 of *Sumo1* proteins detected by our method with $\ell_C = 7.7$. Left: PDB structure 2G4D, shows that the amino acids are in close proximity. Right: Multiple sequence alignment and phylogenetic tree showing the putative compensatory amino acid substitution pair D.N replaced by H.S.

Results. Variant annotated and filtered according to the previous paragraphs lead to ~ 50 million pairs of variants having high log likelihood in our logistic regression model ($\ell_G > 6$, in equation 1.2) that were further analysed under co-evolutionary and Bayesian models. The complete analysis took less than 2 days using a 1,000 CPU-cluster, thus showing that an epistatic GWAS analysis is feasible using current computational resources. Table 1–5 shows the main results from our GWAS epistatic analysis, genes highlighted in red belong to a hand curated set of genes either associated with diabetes or known to be in diabetes related pathway. It should be noted that some of the top results include amino acid modification sites such as Phosphoserine (or Glycosylation, not shown), which are likely to be interaction loci.

Associations are purely epistatic. In order to understand the nature of the putative epistatic associations, we compared our top epistatic GWAS results against a large single marker GWAS study of type II diabetes from the DIAGRAM consortia [64, 57] as well as a meta analysis from the same consortia [44]. For each of our top 1,000 results we looked up the closest entry from DIAGRAM dataset and analysed the corresponding p-values from all the three publicly released DIAGRAM datasets.

Only 14 of the top 1,000 results show suggestive association ($p\text{-value} \leq 10^{-4}$) in a nearby loci (average distance 977 bases). Of these, only one of them is in the top 10 results (8:30982425-T/G variant in *WRN* gene has DIAGRAM p-value of 4.6×10^{-4} and odds ratio 1.06), whereas neither of the others are in the top 50 results. This suggests that our top results are populated by pure epistatic putative effects having no marginal association with disease risk. In light of this evidence, it should be noticed that *conditional search* methods (based on selecting the top single marker

Variant 1			Variant 2			Logistic regression		Co-evolutionary	Combined model
Coordinate	Gene	Functional annotation	Coordinate	Gene	Functional annotation	log ₁₀ (BF)	p-value	Log-Likelihood	log ₁₀ (BF)
20:48129705_G/T_A	PTGIS	STOP_GAINED	16:81348733_G/T	GAN	NON_SYNONYMOUS_CODING	6.94	7.80E-07	2.94	8.21
4:90743415_T/C	SNCA	NON_SYNONYMOUS_CODING	2:179659911_G/A	TTN	NON_SYNONYMOUS_CODING	6.47	2.73E-06	1.50	7.12
3:53213690_G/C	PRKCD	NON_SYNONYMOUS_CODING	14:75746689_C/T	FOS	NON_SYNONYMOUS_CODING	6.43	2.26E-06	2.11	7.35
2:242795125_G/A	PDCD1	NON_SYNONYMOUS_CODING	8:13356801_G/A	DLC1	NON_SYNONYMOUS_CODING	6.36	2.82E-06	1.01	6.80
11:57582923_G/A	CTNND1	AA_modification:Phosphoserine	2:220420784_G/A	OBSL1	NON_SYNONYMOUS_CODING	6.22	3.85E-06	0.29	6.35
1:112298763_T/C	DDX20	NON_SYNONYMOUS_CODING	3:125826058_T/C	ALDH1L1	NON_SYNONYMOUS_CODING	6.07	6.60E-06	4.62	8.08
2:179457146_G/A	TTN	NON_SYNONYMOUS_CODING	22:35695930_C/A	TOM1	NON_SYNONYMOUS_CODING	6.04	4.77E-06	2.72	7.22
1:45797504_C/G	MUTYH	NON_SYNONYMOUS_CODING	8:30982425_T/G	WRN	NON_SYNONYMOUS_CODING	6.00	9.62E-06	2.74	7.20
16:4855278_A/G	GLYR1	AA_modification:Phosphoserine	8:13259100_G/A	DLC1	NON_SYNONYMOUS_CODING	5.90	1.58E-05	3.57	7.45
11:45975129_C/T	PHF21A	NON_SYNONYMOUS_CODING	19:49458190_C/A	BAX	NON_SYNONYMOUS_CODING	5.81	1.55E-05	2.31	6.81
7:128490102_G/A	FLNC	NON_SYNONYMOUS_CODING	8:13357339_G/C	DLC1	NON_SYNONYMOUS_CODING	5.81	1.02E-05	6.60	8.67
11:236090_G/A	SIRT3	NON_SYNONYMOUS_CODING	4:110615838_C/T	CASP6	NON_SYNONYMOUS_CODING	5.79	9.91E-06	1.44	6.42
8:144993930_C/G	PLEC	NON_SYNONYMOUS_CODING	14:73422258_C/G	DCAF4	NON_SYNONYMOUS_CODING	5.79	1.08E-05	4.79	7.87
1:45224997_A/C	KIF2C	NON_SYNONYMOUS_CODING	2:108921032_C/T	SULT1C2	NON_SYNONYMOUS_CODING	5.70	2.30E-05	4.98	7.86
11:134252895_C/T	B3GAT1	NON_SYNONYMOUS_CODING	15:75012984_T/C	CYP11A1	NON_SYNONYMOUS_CODING	5.68	1.56E-05	1.81	6.47
6:116441645_C/G	COL10A1	NON_SYNONYMOUS_CODING	20:30072135_G/A	REM1	NON_SYNONYMOUS_CODING	5.63	1.24E-05	0.08	5.67
1:201016295_G/A	CACNA1S	NON_SYNONYMOUS_CODING	19:17000695_G/A	F2RL3	NON_SYNONYMOUS_CODING	5.61	2.89E-05	4.12	7.40
7:43351409_T/G	HECW1	NON_SYNONYMOUS_CODING	2:219294200_A/G	VIL1	NON_SYNONYMOUS_CODING	5.59	8.39E-07	0.62	5.87
15:67457334_A/G	SMAD3	NON_SYNONYMOUS_CODING	1:201052381_A/G	CACNA1S	NON_SYNONYMOUS_CODING	5.58	2.34E-05	0.60	5.84
10:53822300_A/G	PRKG1	NON_SYNONYMOUS_CODING	9:140007465_G/A	DPP7	NON_SYNONYMOUS_CODING	5.56	1.46E-05	3.30	7.00
2:225362477_C/T	CUL3	NON_SYNONYMOUS_CODING	9:120476787_C/G	TLR4	STOP_GAINED	5.56	2.96E-05	3.16	6.93

Table 1–5: Results from epistatic GWAS analysis of type II diabetes sequencing data. First column shows total $\log_{10}(BF_T)$; second and third columns show p-value and (raw) Bayes factor for logistic regression model. For each variant in the putative interaction pair: genomic coordinate, gene and functional annotation are shown. Genes marked in red are manually curated gene sets form diabetes related pathways

results and performing epistatic analysis only this subset) would have missed most of our top results. Furthermore, our algorithm might be missing any three or higher order pure epistatic interaction, a limitations that doesn't seem to be plausible to overcome without introducing prior biological knowledge of interacting loci (which is obviously not available at the moment).

1.5.4 Power analysis

In order to asses disease association power we performed extensive simulations, as it is often the case in this kind of analysis some simplifying but realistic assumptions were required to make simulations computationally tractable. We assumed that: i) the disease has a logistic risk model; ii) risk model has purely epistatic terms, this means that individual loci are assumed to have no marginal effect in disease risk;

iii) disease prevalence is 8% according the well accepted prevalence for type II diabetes; iv) that cofactors influencing disease such as population admixture, age and sex were perfectly reduced by the model, meaning that no residual effects remains after correction; v) genome wide significance was established as $0.05/(10^6)^2 = 5.10^{-14}$; and vi) that the study has an equal number of cases and controls.

Under these assumptions we calculated power by running 100 iterations for every model having a combination of: i) sample sizes ranging from 10,000 to 1,000,000, ii) log odds disease risk ranging from 0.1 to 5, and iii) allele frequencies of each of the two loci ranging from 1% to 20%. Results for some selected models are shown in Figure 1–6.

As a results form these simulations we observe, as expected, that very large sample sizes are expected to be required to finding epistatic effects on rare variant loci (i.e. allele frequencies below 1%). Even if risk is assumed to be over 2, 3, or 5, sample sizes requirements are expected to be over 400,000, 200,000 and 100,000 respectively (see Figure 1–6, top-left plot). For common variants (i.e. allele frequency of 5%) the sample sizes look more attainable in the near future, ranging from 10,000 to 100,000 samples when risk factors decrease from 5 to 0.6 (Figure 1–6, middle row, left plot). Finally, for relatively common variants (allele frequency of 10%) the sample sizes up to 100,000 would be required for risk factors of 0.3 which is still considered a high risk factor (Figure 1–6, bottom right plot).

These results from our power calculations show once more that large sample sizes are required to find epistatic interactions even under assumptions of relatively




Figure 1–6: Power calculation using a case/control pure two-loci epistatic model for disease prevalences of 8% (type II diabetes). X-axis shows the number of samples in thousands (ranging from 10,000 to 1,000,000) and several joint risk values (from 0.1 to 5) are shown as different colors lines within each plot. Each plot represents a different allele frequencies combination (for each of the two loci), from top to bottom and left to right, the allele frequency value pairs are: $[AF_1 = 1\%, AF_2 = 1\%]$, $[AF_1 = 5\%, AF_2 = 1\%]$, $[AF_1 = 5\%, AF_2 = 2.5\%]$, $[AF_1 = 5\%, AF_2 = 5\%]$, $[AF_1 = 10\%, AF_2 = 1\%]$, $[AF_1 = 10\%, AF_2 = 2.5\%]$, $[AF_1 = 10\%, AF_2 = 5\%]$, $[AF_1 = 10\%, AF_2 = 7.5\%]$, $[AF_1 = 10\%, AF_2 = 10\%]$

common variants and relatively high risk factors. This highlights not only the complexity of finding epistatic genome wide associations but also how elusive these loci can be.

Finally it is worth mentioning that our epistatic GWAS method is able to increase power by using additional information from a co-evolutionary model. According to our calculations, co-evolutionary information can increase Bayes Factor between 10^2 and 10^4 , which is roughly equivalent to reducing genome wide association p-value threshold by two orders of magnitude [23], thus shifting the power curves from Figure 1–6 to the left. Thus the net effect of adding information from a co-evolutionary model is to reduce sample size requirements roughly by half, which is quite remarkable given the little additional information being used by the model (only a multiple sequence alignment).

1.6 Discussion

In this paper, we propose a novel methodology for genome wide association studies of pairs of variants under putative epistatic interaction. Due to the large number of statistical tests required in epistatic analysis, and the corresponding reduction of statistical power, this type of analysis is meant to be applied to datasets consisting of large number of samples, but our highly optimized algorithms are suitable for large scale sequencing genomic studies.

We show the application of our methods to a large scale exome sequencing study for type II diabetes consisting of $\sim 13,000$ samples and $\sim 1,7M$ variants. First, this shows the feasible to apply our methods GWAS-scale datasets. Second, although larger cohorts are needed in order to find risk alleles that have lower frequencies and

are not captured by this study, we show several suggestive association of pairs of putatively interacting variants with type II diabetes.

The co-evolutionary model we propose in section 1.4.1 requires multiple sequence alignment and the corresponding phylogenetic tree. Intuitively, using an *MSA* with larger number of sequences should improve co-evolutionary model detection and other co-evolutionary approaches indeed require very large *MSA*. But *MSA* consisting of a large number of sequences are available only for a small fraction of human proteins, and they often consist of a mixture of ortholog and paralog sequences which may lead to biases. Furthermore, both the tree and the number of sequences in the *MSA* should remain constant throughout the genome in order to take advantage of computational optimizations (matrix exponential precalculation and “constant tree caching”) that allow the algorithm to be applied at genome-wide scale. Some multiple sequence alignments (such as Pfam) usually have different number of sequences for each protein (thus different phylogenetic trees). This poses two main disadvantages for our methodology: i) we cannot benefit from the previously mentioned optimizations, since they require a constant phylogenetic tree throughout the whole genome; and ii) we would add the problem of reconciling different phylogenetic trees from two proteins, which may lead to inconsistencies. For all these reasons we selected UCSC’s multi-100way [30], a genome wide multiple sequence alignment of 100 organisms which has single genome wide phylogenetic tree. This *MSA* is expected to grow with the advent of projects like G10K [25] thus enabling more precise co-evolutionary predictions.

In order to further validate our co-evolutionary model in the context of human disease, we tested whether it can separate clinically relevant variants from ClinVar database [34] according to their clinical significance attribute (CLNSIG). Interestingly, variants categorized as “benign” or “druggable” have higher scores (mean ℓ_C within protein) than variants categorized as pathogenic (Supplementary Tables ??, ?? and Figure 1–10). We speculate that this might be because amino acids that can be compensated would be characterized as “benign” whereas deleterious amino acids changes cannot be compensated by mutation.

Comparison to other Co-Evolutionary methods. There are several methodologies that can be used to predict putative interactions based on co-evolutionary theory. Nevertheless most methods are limited respect to their applicability to GWAS-scale analyses:

Phylogenetic tree similarity can be used as a proxy for the co-evolution of interacting proteins. Computational methods use matrix alignment [49] which has demonstrated some degree of success. Unfortunately, such methods have two limiting factors: i) they require large (distinct) phylogenetic trees for each protein which are not be available for all proteins in the genome; and ii) uses a simulated annealing to match matrices, thus requiring long computational times for each putative pair or proteins.

Correlation methods aim to detect changes on one of the interacting proteins that are compensated by mutations in the other [45, 21]. Although these methods are fast enough to be applicable to GWAS scale studies, they still have at least two limitations: i) they require large number of sequences in the multiple sequence

alignment to overcome noise (as we mentioned large MSAs are not be available throughout the whole genome); and ii) there are well known biases mainly caused by phylogenetic tree and indirect correlations.

Mutual information methods share some similarities with correlation-based methods in the sense that are fast for GWAS studies but unfortunately they also require large MSAs and are well known for having bias caused by phylogenetic tree, and indirect correlations [18]. There are methods based on mutual information than could perform some phylogenetic correction [16], nevertheless they still require a large number of sequences in the MSA and are known to be biased by allele frequencies [17] which might limit their applicability for GWAS studies (particularly on low-frequency variants).

Global models are designed to disentangle direct interactions from indirect ones. Several methods have been proposed which rely on: i) estimating parameters of Boltzmann distributions [35, 59], ii) mean field approximations of Boltzmann distributions [43], iii) constrained optimizations for finding approximations of the inverses of large singular matrices [28], iv) marginalizing multidimensional extensions to mutual information [7]; or v) solving a Bayesian network model [6]. All these models are so computationally heavy that can only be applied to very small sets of proteins. Furthermore, in some of the respective papers the authors mention that it is computationally infeasible to apply them to a single pair of proteins if the length is over a some low number of amino acids (e.g. 60 [59] or 500 [43]). It is therefore not possible to apply any of these method to GWAS-scale studies at the moment.

Our method attempts to solve two of the main problems common to some of the aforementioned methods: i) the requirement of large number of sequence, and ii) the phylogenetic bias. These goals are achieved (at least partially) using a well known Markov model of evolution and optimized algorithms. It should be noted that until not long ago it was thought that methods based on Markov evolutionary theory were unsuitable for large scale studies [16].

Comparison to other Epigenetic GWAS methods. Although there large amounts of evidence supporting the theory that epistasis is ubiquitous, detecting epistatic interactions in human has been quite difficult and despite significant efforts the results have been scarce and difficult to reproduce[67].

Many reasons have been given in this manuscript and elsewhere to indicate why detecting epistasis this is a very difficult task, with the most commonly cited one being the enormous number of statistical tests required, consequently having a significant reduction of statistical power and an increase in computational resources required. Thus methods based on exhaustive search can be computationally infeasible for all but very low order interactions analysis [12]. Their counterpart are *conditional search* methods [36] which are usually based on selecting the top single value associated variants and then performing epistatic analysis on a small subset. Unfortunately these methods are guaranteed to ignore pure epistatic interactions and only detect marginal ones [36, 11]. Since there is no biological indication on whether complex traits have marginal or pure epistatic effects [13, 67, 36], it might not be safe to rely on these type of methods when performing an unbiased association study.

Stochastic search based methods [65] show great potential, but as far as we known they have not yet produced any significant results most likely due to small sample sizes. Some authors pointed out that some of most well known methods may have difficulties with large number of samples [16].

Finally methods based machine learning have been proposed and applied with different degrees of success [33, 12, 36]. One of the main limitations of machine learning methods lies in the fact that the majority of them do not result in a statistical significance metric (such as p-value or Bayesian factor), thus researchers are often weary of conducting an expensive follow up studies based in results from machine learning methodologies. Another limitation is that machine learning approaches may not allow appropriate correction from population admixture and other cofactors.

The methodology we proposed in this paper is based on a well established statistical procedures (Logistic Regression) using gold standard corrections for known population cofactors as well as other disease cofactors (age and sex are known to affect risk of type II diabetes). Our method performs exhaustive search of second order interactions thus is capable of finding pure epistatic interactions as well as marginal ones. Finally, we address the power limitations by using co-evolutionary results from a well established Markov model of evolution and combining them with our association analysis by means of a Bayesian model. This has the advantage that while being based on solid and well accepted theoretical grounds, it can increase statistical power and is capable of analysing large GWAS datasets that are becoming available now.

Our methodology currently cannot analyse variants that are in complete LD, which might seem a limitation given that there is evidence suggesting that genes relatively close (in genomic coordinates) tend to be correlated in expression (co-regulated) and likely to be in the same pathway or even to interact [46]. Nevertheless, it seems that complete LD would be a result of “selective sweeps”, in which an allele giving significant fitness advantage becomes more frequent so rapidly that there is little recombination. These selective sweeps seem to be rare [26], thus we think this issue should be a limitation.

Future work. We plan to extend our method to include context specific information by creating Q_2 estimates for different protein domains. This would allow to obtain better estimates for well characterized protein interaction regions. Another line of work is to perform GWAS using kernel based statistics of multiple variants [62] thus allowing simultaneous analysis of nearby variants in a putative interaction hotspot. In this case the epistatic information would be used as a function modifying the kernel, instead of a Bayesian prior. It has also been suggested that positive selection might be used as an additional prior of epistatic interactions. Nevertheless a study comparing positive selection maps from 9 different methods [2] shows that only 14% of the regions have been identified in more than one study. This striking lack of concordance suggests that using positive selection estimates would add more noise than information at this moment, although it is an interesting venue to explore when more reliable estimates become available.

1.7 Supplementary material




Figure 1–7: Comparison (relative error) between PAM1 and $\hat{P}(t)$ estimated from \hat{Q}





Figure 1-8: \hat{Q}_2 matrix structure




Figure 1–9: Distribution of $\ell_C(k)$ for interacting genes (red) and non-interacting genes (green) showing a small but statistically significant difference.




Figure 1–10: Distribution of ℓ_C across different clinical categories from ClinVar database showing a clear separation on “Benign” variants

References

- [1] Marit Ackermann and Andreas Beyer. Systematic detection of epistatic interactions based on allele pair frequencies. *PLoS genetics*, 8(2):e1002463, 2012.
- [2] Joshua M Akey. Constructing genomic maps of positive selection in humans: Where do we go from here? *Genome research*, 19(5):711–722, 2009.
- [3] D.J. Balding. A tutorial on statistical methods for population association studies. *Nature Reviews Genetics*, 7(10):781–791, 2006.
- [4] Mathieu Blanchette, W James Kent, Cathy Riemer, Laura Elnitski, Arian FA Smit, Krishna M Roskin, Robert Baertsch, Kate Rosenbloom, Hiram Clawson, Eric D Green, et al. Aligning multiple genomic sequences with the threaded blockset aligner. *Genome research*, 14(4):708–715, 2004.
- [5] Charles George Broyden. The convergence of a class of double-rank minimization algorithms 1. general considerations. *IMA Journal of Applied Mathematics*, 6(1):76–90, 1970.
- [6] Lukas Burger and Erik van Nimwegen. Disentangling direct from indirect co-evolution of residues in protein alignments. *PLoS computational biology*, 6(1):e1000633, 2010.
- [7] Greg W Clark, Sharon H Ackerman, Elisabeth R Tillier, and Domenico L Gatti. Multidimensional mutual information methods for the analysis of covariation in multiple sequence alignments. *BMC bioinformatics*, 15(1):157, 2014.
- [8] G.M. Clarke, C.A. Anderson, F.H. Pettersson, L.R. Cardon, A.P. Morris, and K.T. Zondervan. Basic statistical analysis in genetic case-control studies. *Nature protocols*, 6(2):121–133, 2011.
- [9] Onofre Combarros, Mario Cortina-Borja, A David Smith, and Donald J Lehmann. Epistasis in sporadic alzheimer’s disease. *Neurobiology of aging*, 30(9):1333–1349, 2009.

- [10] Diabetes SAT2D Consortium, Diabetes MAT2D Consortium, Anubha Mahajan, Min Jin Go, Weihua Zhang, Jennifer E Below, Kyle J Gaulton, Teresa Ferreira, Momoko Horikoshi, Andrew D Johnson, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nature genetics*, 46(3):234–244, 2014.
- [11] Heather J Cordell. Epistasis: what it means, what it doesn’t mean, and statistical methods to detect it in humans. *Human molecular genetics*, 11(20):2463–2468, 2002.
- [12] Heather J Cordell. Detecting gene–gene interactions that underlie human diseases. *Nature Reviews Genetics*, 10(6):392–404, 2009.
- [13] Robert Culverhouse, Brian K Suarez, Jennifer Lin, and Theodore Reich. A perspective on epistasis: limits of models displaying no main effect. *The American Journal of Human Genetics*, 70(2):461–471, 2002.
- [14] Ingrid Daubechies, Ronald DeVore, Massimo Fornasier, and C Sinan Güntürk. Iteratively reweighted least squares minimization for sparse recovery. *Communications on Pure and Applied Mathematics*, 63(1):1–38, 2010.
- [15] Margaret O Dayhoff and Robert M Schwartz. A model of evolutionary change in proteins. In *In Atlas of protein sequence and structure*. Citeseer, 1978.
- [16] David de Juan, Florencio Pazos, and Alfonso Valencia. Emerging methods in protein co-evolution. *Nature Reviews Genetics*, 14(4):249–261, 2013.
- [17] Stanley D Dunn, Lindi M Wahl, and Gregory B Gloor. Mutual information without the influence of phylogeny or entropy dramatically improves residue contact prediction. *Bioinformatics*, 24(3):333–340, 2008.
- [18] Mario A Fares and Simon AA Travers. A novel method for detecting intramolecular coevolution: adding a further dimension to selective constraints analyses. *Genetics*, 173(1):9–23, 2006.
- [19] Joseph Felsenstein and Joseph Felsenstein. *Inferring phylogenies*, volume 2. Sinauer Associates Sunderland, 2004.
- [20] Hong Gao, Julie M Granka, and Marcus W Feldman. On the classification of epistatic interactions. *Genetics*, 184(3):827–837, 2010.

- [21] Ulrike Göbel, Chris Sander, Reinhard Schneider, and Alfonso Valencia. Correlated mutations and residue contacts in proteins. *Proteins: Structure, Function, and Bioinformatics*, 18(4):309–317, 1994.
- [22] Chern-Sing Goh, Andrew A Bogan, Marcin Joachimiak, Dirk Walther, and Fred E Cohen. Co-evolution of proteins with their interaction partners. *Journal of molecular biology*, 299(2):283–293, 2000.
- [23] Steven N Goodman. Toward evidence-based medical statistics. 2: The bayes factor. *Annals of internal medicine*, 130(12):1005–1013, 1999.
- [24] L Guariguata, DR Whiting, I Hambleton, J Beagley, U Linnenkamp, and JE Shaw. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes research and clinical practice*, 103(2):137–149, 2014.
- [25] David Haussler, Stephen J O’Brien, Oliver A Ryder, F Keith Barker, Michele Clamp, Andrew J Crawford, Robert Hanner, Olivier Hanotte, Warren E Johnson, Jimmy A McGuire, et al. Genome 10k: a proposal to obtain whole-genome sequence for 10 000 vertebrate species. *Journal of Heredity*, 100(6):659–674, 2009.
- [26] Ryan D Hernandez, Joanna L Kelley, Eyal Elyashiv, S Cord Melton, Adam Auton, Gilean McVean, Guy Sella, Molly Przeworski, et al. Classic selective sweeps were rare in recent human evolution. *science*, 331(6019):920–924, 2011.
- [27] Christopher A Hunter, Juswinder Singh, and Janet M Thornton. π - π interactions: The geometry and energetics of phenylalanine-phenylalanine interactions in proteins. *Journal of molecular biology*, 218(4):837–846, 1991.
- [28] David T Jones, Daniel WA Buchan, Domenico Cozzetto, and Massimiliano Pontil. Psicov: precise structural contact prediction using sparse inverse covariance estimation on large multiple sequence alignments. *Bioinformatics*, 28(2):184–190, 2012.
- [29] Luke Jostins, Adam P Levine, and Jeffrey C Barrett. Using genetic prediction from known complex disease loci to guide the design of next-generation sequencing experiments. *PloS one*, 8(10):e76328, 2013.

- [30] Donna Karolchik, Galt P Barber, Jonathan Casper, Hiram Clawson, Melissa S Cline, Mark Diekhans, Timothy R Dreszer, Pauline A Fujita, Luvina Guruvadoo, Maximilian Haeussler, et al. The ucsc genome browser database: 2014 update. *Nucleic acids research*, 42(D1):D764–D770, 2014.
- [31] Robert E Kass and Adrian E Raftery. Bayes factors. *Journal of the american statistical association*, 90(430):773–795, 1995.
- [32] Szymon M Kiełbasa, Raymond Wan, Kengo Sato, Paul Horton, and Martin C Frith. Adaptive seeds tame genomic sequence comparison. *Genome research*, 21(3):487–493, 2011.
- [33] Ching Lee Koo, Mei Jing Liew, Mohd Saberi Mohamad, and Abdul Hakim Mohamed Salleh. A review for detecting gene-gene interactions using machine learning methods in genetic epidemiology. *BioMed research international*, 2013, 2013.
- [34] Melissa J Landrum, Jennifer M Lee, George R Riley, Wonhee Jang, Wendy S Rubinstein, Deanna M Church, and Donna R Maglott. Clinvar: public archive of relationships among sequence variation and human phenotype. *Nucleic acids research*, page gkt1113, 2013.
- [35] Alan Lapedes, Bertrand Giraud, and Christopher Jarzynski. Using sequence alignments to predict protein structure and stability with high accuracy. *arXiv preprint arXiv:1207.2484*, 2012.
- [36] Jing Li, Benjamin Horstman, and Yixuan Chen. Detecting epistatic effects in association studies at a genomic level based on an ensemble approach. *Bioinformatics*, 27(13):i222–i229, 2011.
- [37] John Lonsdale, Jeffrey Thomas, Mike Salvatore, Rebecca Phillips, Edmund Lo, Saboor Shad, Richard Hasz, Gary Walters, Fernando Garcia, Nancy Young, et al. The genotype-tissue expression (gtex) project. *Nature genetics*, 45(6):580–585, 2013.
- [38] Ramamurthy Mani, Robert P St Onge, John L Hartman, Guri Giaever, and Frederick P Roth. Defining genetic interaction. *Proceedings of the National Academy of Sciences*, 105(9):3461–3466, 2008.

- [39] Teri A Manolio, Francis S Collins, Nancy J Cox, David B Goldstein, Lucia A Hindorff, David J Hunter, Mark I McCarthy, Erin M Ramos, Lon R Cardon, Aravinda Chakravarti, et al. Finding the missing heritability of complex diseases. *Nature*, 461(7265):747–753, 2009.
- [40] Debora S Marks, Thomas A Hopf, and Chris Sander. Protein structure prediction from sequence variation. *Nature biotechnology*, 30(11):1072–1080, 2012.
- [41] et. al. McCarthy, Mark. Variation in protein-coding sequence and predisposition to type 2 diabetes. *To be published*, 2015.
- [42] Brett A McKinney, David M Reif, Marylyn D Ritchie, and Jason H Moore. Machine learning for detecting gene-gene interactions. *Applied bioinformatics*, 5(2):77–88, 2006.
- [43] Faruck Morcos, Andrea Pagnani, Bryan Lunt, Arianna Bertolino, Debora S Marks, Chris Sander, Riccardo Zecchina, José N Onuchic, Terence Hwa, and Martin Weigt. Direct-coupling analysis of residue coevolution captures native contacts across many protein families. *Proceedings of the National Academy of Sciences*, 108(49):E1293–E1301, 2011.
- [44] Andrew P Morris, Benjamin F Voight, Tanya M Teslovich, Teresa Ferreira, Ayellet V Segré, Valgerdur Steinthorsdottir, Rona J Strawbridge, Hassan Khan, Harald Grallert, Anubha Mahajan, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nature genetics*, 44(9):981, 2012.
- [45] Florencio Pazos, Manuela Helmer-Citterich, Gabriele Ausiello, and Alfonso Valencia. Correlated mutations contain information about protein-protein interaction. *Journal of molecular biology*, 271(4):511–523, 1997.
- [46] Petko M Petkov, Joel H Graber, Gary A Churchill, Keith DiPetrillo, Benjamin L King, and Kenneth Paigen. Evidence of a large-scale functional organization of mammalian chromosomes. *PLoS genetics*, 1(3):e33, 2005.
- [47] Patrick C Phillips. Epistasisthe essential role of gene interactions in the structure and evolution of genetic systems. *Nature Reviews Genetics*, 9(11):855–867, 2008.
- [48] Alkes L Price, Nick J Patterson, Robert M Plenge, Michael E Weinblatt, Nancy A Shadick, and David Reich. Principal components analysis corrects for

- stratification in genome-wide association studies. *Nature genetics*, 38(8):904–909, 2006.
- [49] Arun K Ramani and Edward M Marcotte. Exploiting the co-evolution of interacting proteins to discover interaction specificity. *Journal of molecular biology*, 327(1):273–284, 2003.
 - [50] Mario X Ruiz-González and Mario A Fares. Coevolution analyses illuminate the dependencies between amino acid sites in the chaperonin system groes-l. *BMC evolutionary biology*, 13(1):156, 2013.
 - [51] Clara M Santiveri and M Jiménez. Tryptophan residues: Scarce in proteins but strong stabilizers of β -hairpin peptides. *Peptide Science*, 94(6):779–790, 2010.
 - [52] Benjamin A Shoemaker and Anna R Panchenko. Deciphering protein–protein interactions. part i. experimental techniques and databases. *PLoS computational biology*, 3(3):e42, 2007.
 - [53] Benjamin A Shoemaker and Anna R Panchenko. Deciphering protein–protein interactions. part ii. computational methods to predict protein and domain interaction partners. *PLoS computational biology*, 3(4):e43, 2007.
 - [54] Chris Stark, Bobby-Joe Breitkreutz, Teresa Reguly, Lorrie Boucher, Ashton Breitkreutz, and Mike Tyers. Biogrid: a general repository for interaction datasets. *Nucleic acids research*, 34(suppl 1):D535–D539, 2006.
 - [55] Aravind Subramanian, Pablo Tamayo, Vamsi K Mootha, Sayan Mukherjee, Benjamin L Ebert, Michael A Gillette, Amanda Paulovich, Scott L Pomeroy, Todd R Golub, Eric S Lander, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences of the United States of America*, 102(43):15545–15550, 2005.
 - [56] Kavitha Venkatesan, Jean-Francois Rual, Alexei Vazquez, Ulrich Stelzl, Irma Lemmens, Tomoko Hirozane-Kishikawa, Tong Hao, Martina Zenkner, Xiaofeng Xin, Kwang-Il Goh, et al. An empirical framework for binary interactome mapping. *Nature methods*, 6(1):83–90, 2009.
 - [57] Benjamin F Voight, Laura J Scott, Valgerdur Steinthorsdottir, Andrew P Morris, Christian Dina, Ryan P Welch, Eleftheria Zeggini, Cornelia Huth, Yurii S

- Aulchenko, Gudmar Thorleifsson, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nature genetics*, 42(7):579–589, 2010.
- [58] Jon Wakefield. Bayes factors for genome-wide association studies: comparison with p-values. *Genetic epidemiology*, 33(1):79–86, 2009.
- [59] Martin Weigt, Robert A White, Hendrik Szurmant, James A Hoch, and Terence Hwa. Identification of direct residue contacts in protein–protein interaction by message passing. *Proceedings of the National Academy of Sciences*, 106(1):67–72, 2009.
- [60] Samuel S Wilks. The large-sample distribution of the likelihood ratio for testing composite hypotheses. *The Annals of Mathematical Statistics*, 9(1):60–62, 1938.
- [61] Andrew R Wood, Tonu Esko, Jian Yang, Sailaja Vedantam, Tune H Pers, Stefan Gustafsson, Audrey Y Chu, Karol Estrada, Jian’an Luan, Zoltán Kutalik, et al. Defining the role of common variation in the genomic and biological architecture of adult human height. *Nature genetics*, 46(11):1173–1186, 2014.
- [62] M.C. Wu, S. Lee, T. Cai, Y. Li, M. Boehnke, and X. Lin. Rare-variant association testing for sequencing data with the sequence kernel association test. *The American Journal of Human Genetics*, 2011.
- [63] Ziheng Yang. *Computational molecular evolution*, volume 284. Oxford University Press Oxford, 2006.
- [64] Eleftheria Zeggini, Laura J Scott, Richa Saxena, Benjamin F Voight, Jonathan L Marchini, Tianle Hu, Paul IW de Bakker, Gonçalo R Abecasis, Peter Alm-gren, Gitte Andersen, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. *Nature genetics*, 40(5):638–645, 2008.
- [65] Yu Zhang and Jun S Liu. Bayesian inference of epistatic interactions in case-control studies. *Nature genetics*, 39(9):1167–1173, 2007.
- [66] Jinying Zhao, Li Jin, and Momiao Xiong. Test for interaction between two unlinked loci. *The American Journal of Human Genetics*, 79(5):831–845, 2006.
- [67] O. Zuk, E. Hechter, S.R. Sunyaev, and E.S. Lander. The mystery of missing heritability: Genetic interactions create phantom heritability. *Proceedings of the National Academy of Sciences*, 109(4):1193–1198, 2012.

- [68] Or Zuk, Stephen F Schaffner, Kaitlin Samocha, Ron Do, Eliana Hechter, Sekar Kathiresan, Mark J Daly, Benjamin M Neale, Shamil R Sunyaev, and Eric S Lander. Searching for missing heritability: Designing rare variant association studies. *Proceedings of the National Academy of Sciences*, 111(4):E455–E464, 2014.